ngµç×ÓÓÎÏ·

03
Ê×Ò³ / ½Ìѧ¿ÆÑÐ / ÕýÎÄ

ÑîÁ®Æ½ÍŶÓÕ¹ÏÖÌìÆø×ª±äÓëÉç»á¾­¼ÃÒòËØÅäºÏ¼Ó¾çÈ«Çò¿¹Î¢ÉúÎïÒ©ÎïÄÍÒ©ÐÔ

¸å¼þȪԴ£º¹«¹²ÎÀÉúѧԺ ±à¼­£ºÎâÁ¢¼á ÉóºË£ºËïÒ«±ó¡¢¡¢¡¢»ÆÑÞ ÔĶÁÁ¿£º

ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±Âí×ÓÊæ¡¢¡¢¡¢ÃÏ·²Ü·£©¿ËÈÕ£¬£¬£¬ngµç×ÓÓÎÏ·¹«¹²ÎÀÉúѧԺÑîÁ®Æ½ÍŶӾ­ÓÉÑо¿£¬£¬£¬Õ¹ÏÖÁËÌìÆø×ª±äÓëÉç»á¾­¼ÃÒòËØ·´¿¹Î¢ÉúÎïÒ©ÎïÄÍÒ©ÐÔ£¨antimicrobial resistance£¬£¬£¬AMR£©µÄЭͬÇýÐж¯Ó㬣¬£¬²¢Í¨¹ýÈ«ÇòÊý¾ÝÆÊÎöÓë¶àÇé¾°Ô¤²â£¬£¬£¬ÎªÎ´À´AMR·À¿ØÌṩÁËÕþ²ßÖ¸Òý¡£Ïà¹ØÐ§¹û½ÒÏþÓÚ¹ú¼Ê¶¥¼¶ÆÚ¿¯Nature Medicine¡£

Ñо¿ÍŶÓÍøÂçÁËÀ´×ÔÈ«Çò101¸ö¹ú¼ÒÓйØÌìÏÂÎÀÉú×éÖ¯ÍÆ¼öµÄ¾ßÓй«¹²ÎÀÉúÖ÷ÒªÐÔµÄÁùÖÖÄÍÒ©¾úµÄ4502ÌõAMR¼à²â¼Í¼£¬£¬£¬Éæ¼°Áè¼Ý3200ÍòÖêÊèÉ¢¾úÖ꣬£¬£¬Ê±¼ä¿ç¶È´Ó1999ÄêÖÁ2022Äê¡£Êý¾ÝȪԴ°üÀ¨ResistanceMap¡¢¡¢¡¢È«Çò¿¹¾úÒ©ÎïÄÍÒ©ÐÔºÍʹÓüà²âϵͳ£¨GLASS£©¡¢¡¢¡¢Å·ÖÞ¿¹¾úÒ©ÎïÄÍÒ©ÐÔ¼à²âÍøÂ磨EARS-Net£©¡¢¡¢¡¢ÖÐÑǺÍÅ·ÖÞ¿¹¾úÒ©ÎïÄÍÒ©ÐÔ¼à²âÍøÂ磨CAESAR£©ÒÔ¼°Öйú¿¹¾úÒ©ÎïÄÍÒ©ÐÔ¼à²âϵͳ£¨CARSS£©¡£Ñо¿ÖÜÈ«ÆÊÎöÁËÉç»á¾­¼ÃºÍÇéÐÎÒòËØ¶ÔAMRµÄÓ°Ï죬£¬£¬ÆÀ¹ÀÁË¡°¿¹Î¢ÉúÎïÒ©ÎïʹÓÃïÔÌ­¡±¡¢¡¢¡¢¡°¿É³ÖÐø¿ªÕ¹½¨Ò顱ÒÔ¼°ÌìÆø×ª±äϹ²ÏíÉç»á¾­¼Ã·¾¶£¨SSPs£©³¡¾°ÏÂAMRµÄ¿ªÕ¹Ç÷ÊÆ¡£

Ñо¿·¢Ã÷£¬£¬£¬×Ô2000ÄêÒÔÀ´£¬£¬£¬ËùÓÐÊÕÈë×é±ðµÄ¹ú¼ÒAMRÊ¢ÐÐÂʾùÓÐËùÉÏÉý£¨0.4% [95%CI: -3.2% - 4.1%]£©£¬£¬£¬µ«¸ßÊÕÈë¹ú¼ÒµÄAMRÊ¢ÐÐÂÊÔöÌíËÙÂʽÏÂý£¨0.3% [95% CI: -0.5% - 3.8%]£©¡£³ý̼ÇàùϩÄÍÒ©Í­Â̼ٵ¥°û¾ú£¨CRPA£©Í⣬£¬£¬ÆäËûËùÓÐÄÍÒ©¾úÊ¢ÐÐÂʾù³ÊÉÏÉýÇ÷ÊÆ£¬£¬£¬ÆäÖÐÈý´úÍ·æßÄÍÒ©´ó³¦°£Ï£¾ú£¨3GCREC£©µÄÔöÌíËÙÂÊ×î¿ì¡£

33B26ED17904F97E2703F13FA9E_FB5D645A_CF25D

²î±ðÊÕÈë¹ú¼Ò·Ö×éAMRµÄת±äÇ÷ÊÆ

Ñо¿Ð§¹û¶ÔÈ«ÇòÓÈÆäÊÇÖеÍÊÕÈë¹ú¼ÒµÄAMRÖÎÀí¾ßÓÐÖ÷ÒªÕþ²ßÆôʾ¡£2024ÄêÁªºÏ¹úAMR¸ß¼¶±ð¾Û»áÉÏ£¬£¬£¬Ìá³öÁ˵½2030ÄêÈ«ÇòAMRÏà¹ØéæÃüÂÊïÔÌ­10%µÄÄ¿µÄ¡£¸ÃÑо¿ÎªÈ«ÇòAMRÖÎÀíÌṩÁËÖ÷ÒªµÄ¿ÆÑ§Ö¤¾Ý£¬£¬£¬²¢½øÒ»²½Ö§³Ö¸÷¹úÖÆ¶©ÇкÏ×ÔÉíÉç»á¾­¼Ã¿ªÕ¹Ë®Æ½µÄÓÐÓøÉÔ¤Õ½ÂÔ¡£ÔÚÌìÆø×ª±äÓëÈ«Çò¿µ½¡ÌôÕ½ÈÕÒæÑÏËàµÄÅä¾°Ï£¬£¬£¬Íƶ¯AMR·À¿ØÄÉÈë¿É³ÖÐø¿ªÕ¹Õ½ÂÔ£¬£¬£¬ÒѳÉΪȫÇòÎÀÉúÕþ²ßµÄÖ÷ҪƫÏò¡£

ÂÛÎÄÁ´½Ó£ºhttps://doi.org/10.1038/s41591-025-03629-3



¡¾ÍøÕ¾µØÍ¼¡¿